drugset / Trial / NCT00514761

Phase II Efficacy Study of AZD6244 in Colorectal Cancer

NCT00514761

Phase 2 Completed 64 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess if there is benefit when using AZD6244 in the treatment if metastatic colorectal cancer in comparison with another treatment called capecitabine. This study will also assess how safe and well tolerated AZD6244 is.

Timeline

Start
2006-09
Primary completion
2007-06
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Capecitabine Small molecule Oral
Subject Selumetinib Small molecule Oral

Indications